KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Debt: 2019-2025

Historic Non-Current Debt for Rigel Pharmaceuticals (RIGL) over the last 6 years, with Sep 2025 value amounting to $30.0 million.

  • Rigel Pharmaceuticals' Non-Current Debt fell 49.85% to $30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.0 million, marking a year-over-year decrease of 49.85%. This contributed to the annual value of $52.4 million for FY2024, which is 0.07% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Non-Current Debt stood at $30.0 million for Q3 2025, which was down 19.98% from $37.5 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Non-Current Debt high stood at $59.8 million for Q3 2024, and its period low was $19.8 million during Q1 2021.
  • Over the past 3 years, Rigel Pharmaceuticals' median Non-Current Debt value was $52.4 million (recorded in 2024), while the average stood at $50.9 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Non-Current Debt skyrocketed by 101.89% in 2021, and later crashed by 49.85% in 2025.
  • Rigel Pharmaceuticals' Non-Current Debt (Quarterly) stood at $19.9 million in 2021, then surged by 98.09% to $39.4 million in 2022, then spiked by 32.76% to $52.4 million in 2023, then rose by 0.07% to $52.4 million in 2024, then plummeted by 49.85% to $30.0 million in 2025.
  • Its last three reported values are $30.0 million in Q3 2025, $37.5 million for Q2 2025, and $44.9 million during Q1 2025.